Roivant Sciences Ltd. ROIV
Institutional shares held
496 Million
3.67M
calls
754K
puts
Total value of holdings
$5.57B
$41.2M
calls
$8.46M
puts
Market Cap
$7.9B
704,382,976
Shares Out.
Institutional ownership
70.46%
# of Institutions
334
We take great care to ensure that the data presented and summarized in this overview for Roivant Sciences Ltd. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ROIV
View all-
Qvt Financial LP New York, NY65.8MShares$738 Million69.8% of portfolio
-
Sb Investment Advisers (Uk) LTD London, X061.9MShares$694 Million5.69% of portfolio
-
Viking Global Investors LP46MShares$516 Million1.55% of portfolio
-
Vanguard Group Inc Valley Forge, PA40.8MShares$457 Million0.01% of portfolio
-
Morgan Stanley New York, NY35.9MShares$403 Million0.03% of portfolio
-
Black Rock Inc. New York, NY35.4MShares$397 Million0.01% of portfolio
-
State Street Corp Boston, MA18.9MShares$212 Million0.01% of portfolio
-
Rubric Capital Management LP New York, NY17.8MShares$199 Million5.14% of portfolio
-
Patient Square Capital LP Menlo Park, CA12.5MShares$140 Million52.09% of portfolio
-
Two Seas Capital LP Rye, NY10.1MShares$114 Million3.67% of portfolio
Latest Institutional Activity in ROIV
Top Purchases
Top Sells
About ROIV
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
Insider Transactions at ROIV
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 28
2025
|
Richard Pulik CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,653
-0.41%
|
$18,183
$11.39 P/Share
|
|
Jun 25
2025
|
Qvt Financial LP |
SELL
Other acquisition or disposition
|
Indirect |
36,756,758
-66.47%
|
-
|
|
Jun 25
2025
|
Keith S Manchester |
SELL
Other acquisition or disposition
|
Indirect |
17,389,525
-49.71%
|
-
|
|
Jun 25
2025
|
Daniel Allen Gold |
SELL
Other acquisition or disposition
|
Indirect |
36,756,758
-66.47%
|
-
|
|
Jun 20
2025
|
Eric Venker President & COO |
SELL
Open market or private sale
|
Direct |
100,000
-6.4%
|
$1,100,000
$11.45 P/Share
|
|
Jun 20
2025
|
Eric Venker President & COO |
BUY
Exercise of conversion of derivative security
|
Direct |
100,000
+6.02%
|
$300,000
$3.85 P/Share
|
|
Jun 20
2025
|
Richard Pulik CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,503
-0.38%
|
$16,533
$11.45 P/Share
|
|
Jun 20
2025
|
Vivek Ramaswamy > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
577,007
-1.52%
|
$6,347,077
$11.46 P/Share
|
|
Jun 18
2025
|
Vivek Ramaswamy > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
565,266
-1.47%
|
$6,217,926
$11.45 P/Share
|
|
Jun 06
2025
|
Vivek Ramaswamy > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
200,800
-0.52%
|
$2,208,800
$11.19 P/Share
|
|
Jun 04
2025
|
Vivek Ramaswamy > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
547,430
-1.4%
|
$6,021,730
$11.34 P/Share
|
|
Jun 03
2025
|
Eric Venker President & COO |
SELL
Open market or private sale
|
Direct |
566,278
-27.92%
|
$6,229,058
$11.22 P/Share
|
|
Jun 03
2025
|
Eric Venker President & COO |
BUY
Exercise of conversion of derivative security
|
Direct |
785,026
+27.9%
|
$2,355,078
$3.85 P/Share
|
|
Jun 02
2025
|
Eric Venker President & COO |
SELL
Open market or private sale
|
Direct |
433,722
-25.86%
|
$4,770,942
$11.07 P/Share
|
|
Jun 02
2025
|
Eric Venker President & COO |
BUY
Exercise of conversion of derivative security
|
Direct |
600,000
+26.35%
|
$1,800,000
$3.85 P/Share
|
|
May 28
2025
|
Richard Pulik CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,653
-0.41%
|
$16,530
$10.62 P/Share
|
|
May 20
2025
|
Matthew Gline CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
10,945
-0.06%
|
$120,395
$11.04 P/Share
|
|
May 20
2025
|
Eric Venker President & COO |
SELL
Open market or private sale
|
Direct |
100,000
-8.49%
|
$1,000,000
$10.95 P/Share
|
|
May 20
2025
|
Eric Venker President & COO |
BUY
Exercise of conversion of derivative security
|
Direct |
100,000
+7.83%
|
$300,000
$3.85 P/Share
|
|
May 20
2025
|
Eric Venker President & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
39,148
-3.51%
|
$430,628
$11.04 P/Share
|
Last 12 Months Summary
Buy / Acquisition
57.6M
Shares
From
16
Insiders
| Grant, award, or other acquisition | 36.6M shares |
|---|---|
| Exercise of conversion of derivative security | 7.57M shares |
| Bona fide gift | 13.4M shares |
Sell / Disposition
124M
Shares
From
25
Insiders
| Payment of exercise price or tax liability | 315K shares |
|---|---|
| Other acquisition or disposition | 95.1M shares |
| Open market or private sale | 15.7M shares |
| Bona fide gift | 13.4M shares |